On October 7, 2026, the National Women's Law Center (NWLC) published Intended vs. Implemented: The Still Unfulfilled Promise of the Affordable Care Act's Birth Control Benefit. The report draws on more than a decade of calls to the center's CoverHer Hotline. Under the ACA, nearly all private plans, Marketplace plans and Medicaid-expansion coverage must cover the full range of contraceptives and related services with no copays, coinsurance or deductibles. NWLC says that thousands of callers, "regardless of insurance type, geographic location, or method of contraception," still hit unlawful denials, surprise charges and administrative barriers.

Why It Matters

For contraceptive innovators, a new method is only as accessible as payers allow, whatever the FDA approves. The pattern NWLC describes, where insurers say "we already cover something similar," hits hardest at the newest products. That includes non-hormonal options like Phexxi and the copper IUD **MIUDELLA**, which Organon plans to launch in late 2026 ([our coverage](/stories/organon-miudella-hormone-free-iud)). Telehealth contraception platforms built on the zero-cost-sharing promise face the same friction from prior-authorization and step-therapy rules. The report's fixes are aimed at states and other enforcers, a sign that advocates expect little federal enforcement in the near term. For investors, payer access needs as much diligence as clinical data in this category.

The report identifies four recurring patterns of what it calls "insurer misconduct." Plans exclude whole categories of contraceptive methods. They deny services that are part of contraceptive care, such as office visits, ultrasounds, anesthesia for sterilization surgery and follow-up. They impose unlawful medical management, including "try and fail" protocols, age limits and refusals to cover brand-name products or sterilization. And they fail to offer a usable way to get the specific product a patient needs, pushing people into prior-authorization and appeal processes that "delay care and discourage people from asserting their rights." Callers reach the hotline after "paying hundreds or thousands of dollars for products and services that should be free," spending months contesting denials, or giving up on care.

Report co-author Lauren Wallace, NWLC senior counsel, told The American Independent (republished by The Michigan Independent on October 16) that the problem has shifted toward newer and more expensive methods. "One that people don't think about very often is the contraceptive gel. It's called Phexxi," she said. The 12-month vaginal ring Annovera is another example. "You saw a lot of pushback from insurance providers saying, Oh no, we already cover NuvaRing, we don't need to cover Annovera, or, We already cover this spermicide, we don't need to cover Phexxi." Wallace called the current period "a make-or-break moment" for enforcing the rules.

Sources

Update — 2026-10-19

Initial entry — story first created.